Patents by Inventor Peter Herrlich

Peter Herrlich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20070232696
    Abstract: The present invention relates to the use of the drug valproic acid and derivatives thereof as inhibitors of enzymes having histone deacetylase activity. The invention also relates to the use of those compounds for the manufacture of a medicament for the treatment of diseases which are associated with hypoacetylation of histones or in which induction of hyperacetylation has a beneficial effect for example by induction of differentiation and/or apoptosis in transformed cells.
    Type: Application
    Filed: January 17, 2007
    Publication date: October 4, 2007
    Inventors: Martin Gottlicher, Thorsten Heinzel, Bernd Groner, Peter Herrlich
  • Patent number: 7265154
    Abstract: The present invention relates to the use of the drug valproic acid and derivatives thereof as inhibitors of enzymes having histone deacetylase activity. The invention also relates to the use of those compounds for the manufacture of a medicament for the treatment of diseases which are associated with hypoacetylation of histones or in which induction of hyperacetylation has a beneficial effect for example by induction of differentiation and/or apoptosis in transformed cells.
    Type: Grant
    Filed: July 5, 2001
    Date of Patent: September 4, 2007
    Assignee: Georg-Speyter-Haus Chemotherapeutisches Forschungsinstitut
    Inventors: Martin Göttlicher, Thorsten Heinzel, Bernd Groner, Peter Herrlich
  • Publication number: 20060166287
    Abstract: The present invention relates to a method for identifying compounds which suppress and/or delay the development of invasive or metastasizing tumor cells of the colon, of the pancreas, of the ovaries or of the thyroid.
    Type: Application
    Filed: May 30, 2003
    Publication date: July 27, 2006
    Inventors: Helmut Ponta, Peter Herrlich, Chen Linfeng, Veronique Orian-Rousseau
  • Publication number: 20050038113
    Abstract: The present invention relates to the use of the drug valproic acid and derivatives thereof as inhibitors of enzymes having histone deacetylase for the sensitizing treatment of human cancers in combination with established therapeutic principles. The invention also relates to the use of those compounds for the treatment of tumor metastasis and minimal residual disease. The invention includes the manufacture of a clinically used substance for the treatment of human cancers.
    Type: Application
    Filed: September 17, 2002
    Publication date: February 17, 2005
    Applicant: G2M Cancer Drugs AG
    Inventors: Bernd Groner, Thorsten Heinzel, Bernd Hentsch, Winfried Wels, Peter Herrlich, Saverio Minucci, Pier Pelicci, Martin Gott Icher
  • Publication number: 20040265804
    Abstract: The present invention relates to a method for identifying and treating metastasizing tumor cells and to a population of cDNA sequences of metastasis-specific genes for use as tumor markers for identifying human cells and/or tissues possessing metastasis potential and for the therapy of cancer diseases.
    Type: Application
    Filed: November 24, 2003
    Publication date: December 30, 2004
    Inventors: Oliver von Stein, Andrea Nestl, Martin Hofmann, Jonathan Sleemann, Peter Herrlich
  • Publication number: 20040087652
    Abstract: The present invention relates to the use of the drug valproic acid and derivatives thereof as inhibitors of enzymes having histone deacetylase activity. The invention also relates to the use of those compounds for the manufacture of a medicament for the treatment of diseases which are associated with hypoacetylation of histones or in which induction of hyperacetylation has a beneficial effect for example by induction of differentiation and/or apoptosis in transformed cells.
    Type: Application
    Filed: August 11, 2003
    Publication date: May 6, 2004
    Inventors: Martin Gttlicher, Thorsten Heinzel, Bernd Groner, Peter Herrlich
  • Publication number: 20040072171
    Abstract: The present invention relates to a method for identifying compounds which modify the activity of the intracellular tumor suppressor gene nf2, where the activity of the protein NF2, which is encoded by the gene nf2, is modified by an extracellular interaction of the compounds with the cell surface protein CD44.
    Type: Application
    Filed: May 13, 2003
    Publication date: April 15, 2004
    Inventors: Helen Morrison, Helmut Ponta, Peter Herrlich
  • Publication number: 20030172393
    Abstract: The present invention relates to a non-human mammal whose glucocorticoid receptor (GR) is modified as regards its inducing function. Furthermore, this invention concerns a process for the production of such a mammal as well as its use for testing chemicals, pharmaceutical preparations and therapeutic approaches.
    Type: Application
    Filed: December 23, 2002
    Publication date: September 11, 2003
    Inventors: Holger Reichardt, Gunther Schutz, Klaus Kastner, Peter Herrlich
  • Publication number: 20020165153
    Abstract: The invention relates to transcription factors with a DNA binding domain consisting of a basic domain and an adjacent leucine zipper domain. The aim of the invention is to provide modified transcription factors whose binding behavior towards each other and towards DNA sequences can be manipulated. To this end, at least one amino acid on the leucine zipper is replaced by a charged amino acid.
    Type: Application
    Filed: January 11, 2002
    Publication date: November 7, 2002
    Inventors: Peter Angel, Peter Herrlich, Hans Van Dam, Alex Van Der Eb
  • Publication number: 20020160010
    Abstract: The present invention relates to the use of anti-CD44 antibodies of both the constant (sDC44) and the variable part of CD44 (vCD44) for treating certain tumours and other diseases associated with the degeneration and activation of Langerhans cells (LC) and dendritic cells (DC) inside a mammalian body, including humans, and for treating undesirable immune reactions.
    Type: Application
    Filed: November 2, 1999
    Publication date: October 31, 2002
    Inventors: PETER HERRLICH, HELMUT PONTA, JAN SIMON, JOHANNES WEISS
  • Patent number: 6391301
    Abstract: The present invention relates to a novel composition for identifying and suppressing the growth of tumor cells, which comprises antibodies which react with proteins having N-glycosidically bonded saccharides.
    Type: Grant
    Filed: August 16, 1999
    Date of Patent: May 21, 2002
    Assignee: Forschungszentrum Karlsruhe GmbH
    Inventors: Jonathan Sleeman, Helmut Ponta, Peter Herrlich, Kim Untae
  • Patent number: 6010865
    Abstract: The invention relates to a process for diagnosing and analysing tumours which is based on detecting the expression of certain variant exons of the CD44-gene. Detection may be carried out at the protein or nucleic acid level. In a preferred embodiment the expression is detected in biopsy material using exon-specific antibodies. Thus, for example, v6-expression is a suitable prognostic parameter for breast cancer, the expression of a transitional epitope which is coded by exons v7 and v8 serves to diagnose cervical cancer.
    Type: Grant
    Filed: June 3, 1996
    Date of Patent: January 4, 2000
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Helmut Ponta, Karl-Heinz Heider, Peter Herrlich, Steven T. Pals, Peter Dall
  • Patent number: 5951982
    Abstract: The present invention relates to a method of reducing or suppressing an immune response with antibodies specific for variants of the glycoprotein CD44. The invention further relates to a method of preventing or treating an immunoregulatory disorder or disease with these antibodies.
    Type: Grant
    Filed: December 20, 1994
    Date of Patent: September 14, 1999
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Margot Zoller, Peter Herrlich, Helmut Ponta
  • Patent number: 5885575
    Abstract: The inventon relates to antibodies that react with a variant epilope in the extracellular region of a variant CD44 polypeptide, wherein the variant epitope has the amino acid sequence:I S S T I S T T P R A P D H T K Q N Q D W T Q W N P S H S N P EV L L Q T T T R M T D V D R N G T T A Y E G N W N P E A H P P LI H H E H H E E E E T P H S T S T I O A T P S S T T E E T A T QK E Q W F G N R W H E G Y R Q T P R E D S H S T T G T A A A S AH T S H P M Q G R T T P S P E D S S W T D F F N P I S H P M G RG H Q A G R R (residues 53-219 of SEQ ID NO:4). Methods of using the antibodies to identify variant epitopes also are provided.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: March 23, 1999
    Assignees: Kernforschungszentrum Karlsruhe GmbH, Universitaet Karlsruhe, Deutsches Krebsforschungszentrum
    Inventors: Peter Herrlich, Helmut Ponta, Ursula Guenthert, Siegfried Matzku, Achim Wenzel
  • Patent number: 5760178
    Abstract: A monoclonal antibody (MAb1.1ASML) directed against a surface glycoprotein of the metastasizing rat pancreatic carcinoma cell line BSp73ASML, was used to identify and isolate a complementary DNA (cDNA) clone capable of encoding for a glycoprotein with partial homology to CD44, a presumed adhesion molecule. This clone, which was subsequently designated pMeta-1, contains an additional extracellular domain of 162 amino acids inserted into the CD44 protein between amino acid positions 223 and 247 (by analogy to human and murine CD44). This new variant was expressed only in the metastasizing cell lines of two rat tumors, the pancreatic carcinoma BSp73 and the mammary adenocarcinoma 13762NF; it was not expressed in non-metastasizing tumor cell lines nor in normal rat tissues. Overexpression of pMeta-1 in the nonmetastasizing BSp73AS cell line suffices to establish full metastatic behavior. The variant-specific rat CD44 sequence was used to isolate a cDNA clone encoding for a human homologue as well.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 2, 1998
    Assignees: Kernforschungszentrum Karlsruhe GmbH, Universitaet Karlsruhe, Krebsforschungszentrum
    Inventors: Peter Herrlich, Helmut Ponta, Ursula Guenthert, Siegfried Matzku, Achim Wenzel
  • Patent number: 5506119
    Abstract: The presence of certain extracellular regions ("ECR") from human and rat variants of the CD44 membrane glycoprotein have been found to be associated with metastasis ability in tumor cells. Isolated polynucleotides encoding the ECRs permit expression of the ECR polypeptide, which in turn can be used as an antigen to obtain monoclonal antibodies that recognize the ECR polypeptide. The anti-ECR monoclonal antibodies have the ability to prevent metastasis by tumor cells that would otherwise metastasize and spread.
    Type: Grant
    Filed: November 9, 1992
    Date of Patent: April 9, 1996
    Assignees: Kernforschungszentrum Karlsruhe GmbH, Universitaet Karlsruhe, Deutsches Krebsforschungszentrum
    Inventors: Peter Herrlich, Helmut Ponta, Ursula Guenthert, Siegfried Matzku, Achim Wenzel